Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

gridegalutamide

An orally bioavailable androgen receptor (AR) degrader, with potential antineoplastic activity. Upon administration, gridegalutamide causes degradation of AR, prevents AR-mediated signaling and inhibits the proliferation of AR-overexpressing tumor cells. AR plays a key role in tumor cell proliferation in castration-resistant prostate cancer (CRPC).

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	Androgen Receptor Degrader CC-94676 AR degrader CC-94676
Code name:	BMS 986365 BMS 986409 BMS-986365 BMS-986409 BMS986365 BMS986409 CC 1083611 CC 94676 CC-1083611 CC-94676 CC1083611 CC94676 CEL 010355 CEL-010355 CEL010355

gridegalutamide

Search NCI's Drug Dictionary